Abstract

Attenuated vaccine strains of lumpy skin disease virus (LSDV) have become increasingly popular as recombinant vaccine vectors, to target both LSDV, as well as other pathogens, including human infectious agents. Historically, these vaccine strains and recombinants were generated in primary (lamb) testis (LT) cells, Madin–Darby bovine kidney (MDBK) cells or in eggs. Growth in eggs is a laborious process, the use of primary cells has the potential to introduce pathogens and MDBK cells are known to harbor bovine viral diarrhea virus (BVDV). In this study, data is presented to show the growth of an attenuated LSDV strain in baby hamster kidney (BHK-21) cells. Subsequently, a recombinant LSDV vaccine was generated in BHK-21 cells. Partial growth was also observed in rabbit kidney cells (RK13), but only when the vaccinia virus host range gene K1L was expressed. Despite the limited growth, the expression of K1L was enough to serve as a positive selection marker for the generation of recombinant LSDV vaccines in RK13 cells. The simplification of generating (recombinant) LSDV vaccines shown here should increase the interest for this platform for future livestock vaccine development and, with BHK-21 cells approved for current good manufacturing practice, this can be expanded to human vaccines as well.

Highlights

  • Poxviruses have a long history of being used as vectors for recombinant vaccines [1,2].Most of the registered recombinant poxvirus vaccines are for veterinary use and include the canarypox virus (CNPV) based vector ALVAC for diseases such as rabies, feline leukaemia virus and equine influenza [3,4,5]

  • Host-restricted poxviruses are important as vaccine vectors because they have

  • Host-restricted poxviruses are important as vaccine vectors because they have nuinduce good immune responses

Read more

Summary

Introduction

Most of the registered recombinant poxvirus vaccines are for veterinary use and include the canarypox virus (CNPV) based vector ALVAC for diseases such as rabies, feline leukaemia virus and equine influenza [3,4,5]. Due to their safety profiles, the majority of poxviruses being explored for human use do not complete their replication cycle in humans and include canarypox virus, various vaccinia virus strains and lumpy skin disease virus (LSDV) [6,7,8,9,10]. It is given as a boost in a heterologous Ebola vaccination regimen with an Adenovirus vectored priming vaccine

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call